Fate Therapeutics
FATE· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -40.4% in FY2025
Bahram Valamehr, Ph.D. is the CEO of Fate Therapeutics and was paid $2.2M in FY2025 (Dec), down 37%.
Pay$100 in the stock at the end of FY21 → $2
Executives3
See all- 1Bahram Valamehr, Ph.D.President, Chief Executive Officer and DirectorFY2025
- 2Cindy R. Tahl, J.D.Chief Legal & Compliance Officer and Corporate SecretaryFY2025
- 3Kamal Adawi, M.S., MBAChief Financial Officer and TreasurerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allFate Therapeutics paid its 3 named executives $4.1M in total in FY2025 (Dec). CEO Bahram Valamehr, Ph.D. was paid $2.2M of that.
| Name | |||
|---|---|---|---|
| Bahram Valamehr, Ph.D.President, Chief Executive Officer and Director | |||
| Cindy R. Tahl, J.D.Chief Legal & Compliance Officer and Corporate Secretary | |||
| Kamal Adawi, M.S., MBAChief Financial Officer and Treasurer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Fate Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Robert S. Epstein, M.D., M.S.Director · 11 yr on the boardIndependentPresident, Chief Executive Officer, and Director—Paid as an executive
- Michael LeeDirector · 7 yr on the boardIndependentPresident, Chief Executive Officer, and Director—Paid as an executive
- Karin Jooss, Ph.D.Director · 6 yr on the boardIndependentPresident, Chief Executive Officer, and Director—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 17, 2025 | FY2024 |
| Annual report | 10-K | Mar 5, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 26, 2024 | FY2023 |
